Glenn Eisenberg Net Worth

The estimated Net Worth of Glenn A Eisenberg is at least $40 million dollars as of 15 August 2024. Mr. Eisenberg owns over 15,000 units of Labcorp stock worth over $6,830,076 and over the last 21 years he sold LH stock worth over $24,352,501. In addition, he makes $8,822,760 as Chief Financial Officer et Executive Vice President at Labcorp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Eisenberg LH stock SEC Form 4 insiders trading

Glenn has made over 38 trades of the Labcorp stock since 2011, according to the Form 4 filled with the SEC. Most recently he sold 15,000 units of LH stock worth $3,359,850 on 15 August 2024.

The largest trade he's ever made was selling 34,504 units of Labcorp stock on 21 February 2024 worth over $7,451,829. On average, Glenn trades about 2,431 units every 34 days since 2004. As of 15 August 2024 he still owns at least 31,289 units of Labcorp stock.

You can see the complete history of Mr. Eisenberg stock trades at the bottom of the page.

Glenn Eisenberg biography

Glenn A. Eisenberg serves as Chief Financial Officer, Executive Vice President of the Company. Mr. Eisenberg received his Bachelor of Arts degree from Tulane University in 1982 and his Master of Business Administration from Georgia State University in 1988. From 2002 until joining the Company, he served as the Executive Vice President of Finance and Administration and Chief Financial Officer at The Timken Company, a $4.3 billion leading global manufacturer of highly engineered bearings and alloy steels and related products and services. Previously, he served as President and Chief Operating Officer of United Dominion Industries, now a subsidiary of SPX Corporation, after working in several roles in finance, including Executive Vice President and Chief Financial Officer. Mr. Eisenberg serves on the Board of Directors of US Ecology, Inc. (NASDAQ: ECOL) since December 2018, and as a director of Perspecta Inc. (NYSE: PRSP) since May 2019. Mr. Eisenberg served on the Boards of Directors of Family Dollar Stores Inc. until July 2015, where he chaired the Audit Committee; and Alpha Natural Resources Inc. until May 2015, where he was the lead independent director and chaired the Nominating and Corporate Governance Committee.

What is the salary of Glenn Eisenberg?

As the Chief Financial Officer et Executive Vice President of Labcorp, the total compensation of Glenn Eisenberg at Labcorp is $8,822,760. There are no executives at Labcorp getting paid more.

How old is Glenn Eisenberg?

Glenn Eisenberg is 58, he's been the Chief Financial Officer et Executive Vice President of Labcorp since 2014. There are 11 older and 12 younger executives at Labcorp. The oldest executive at Labcorp Holdings Inc. is Jean-Luc Belingard, 71, who is the Independent Director.

What's Glenn Eisenberg's mailing address?

Glenn's mailing address filed with the SEC is 531, South Spring Street, Burlington, Alamance County, North Carolina, 27215, United States.

Insiders trading at Labcorp

Over the last 19 years, insiders at Labcorp have traded over $236,972,149 worth of Labcorp stock and bought 10,666 units worth $1,520,331 . The most active insiders traders include Mahon Thomas P Mac, Garheng Kong et David P King. On average, Labcorp executives and independent directors trade stock every 11 days with the average trade being worth of $2,652,442. The most recent stock trade was executed by Der Vaart Sandra D Van on 19 August 2024, trading 2,000 units of LH stock currently worth $454,100.

What does Labcorp do?

recognized for our innovation, quality, and customer convenience, labcorp delivers timely, accurate results for improved patient care. with scientific expertise in esoteric testing, genomics, and clinical and anatomic pathology, labcorp performs more than one million tests on approximately 400,000 samples each day. labcorp is a pioneer in applying advances in medicine and science to laboratory testing, with more than 35 years of experience in serving physicians and their patients. labcorp operates a sophisticated laboratory network, with corporate headquarters in burlington, nc, and more than 34,000 employees worldwide. our more than 220,000 clients include physician offices, hospitals, managed care organizations, and biotechnology and pharmaceutical companies. laboratory corporation of america holdings is listed on the new york stock exchange (nyse) under ticker symbol lh.

Complete history of Mr. Eisenberg stock trades at US Ecology, Labcorp, Timken Co et Perspecta Inc

Labcorp executives and stock owners

Labcorp executives and other stock owners filed with the SEC include:

• Glenn Eisenberg,
  Chief Financial Officer, Executive Vice President
• Adam Schechter,
  President, Chief Executive Officer, Director
• Adam H. Schechter,
  Pres, CEO & Chairman
• Brian Caveney,
  Executive Vice President, President, Diagnostics and Chief Medical Officer
• Lance Berberian,
  Executive Vice President, Chief Technology Officer, Chief Information Officer
• Mark Schroeder,
  Executive Vice President, President of Diagnostics Laboratory Operations and Global Supply Chain
• Glenn A. Eisenberg,
  CFO & Exec. VP
• Mark S. Schroeder,
  Exec. VP and Pres of Diagnostics Laboratory Operations & Global Supply Chain
• Dr. Paul R. Kirchgraber M.D.,
  Exec. VP & CEO of Covance Drug Devel.
• Dr. Brian J. Caveney M.P.H., M.D., J.D., MPH,
  Exec. VP, Pres of Diagnostics & Chief Medical Officer
• Peter Neupert,
  Lead Independent Director
• Kerrii Anderson,
  Independent Director
• Garheng Kong,
  Independent Director
• Robert Williams,
  Independent Director
• Richelle Parham,
  Independent Director
• D. Gary Gilliland,
  Independent Director
• Jean-Luc Belingard,
  Independent Director
• Jeffrey Davis,
  Independent Director
• Clarissa Willett,
  Vice President, Investor Relations
• Peter Wilkinson,
  Senior Vice President, Chief Accounting Officer
• Paul Kirchgraber,
  Executive Vice President and Chief Executive Officer - Covance Drug Development
• Sandra Van Der Vaart,
  Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary
• Amy Summy,
  Executive Vice President, Chief Marketing Officer
• Judith Seltz,
  Chief Human Resource Officer, Executive Vice President
• Chas Cook,
  VP of Investor Relations
• Dr. Marcia T. Eisenberg Ph.D.,
  Chief Scientific Officer & Sr. VP
• Lance V. Berberian,
  Exec. VP and Chief Information & Technology Officer
• Peter J. Wilkinson,
  Sr. VP & Chief Accounting Officer
• Dr. Michelle Abelson Ph.D.,
  Laboratory Director of Operations
• Anita Z Graham,
  EVP, CHRO
• R Sanders Williams,
  Director
• Edward T Dodson,
  Principal Accounting Officer
• Lisa J Uthgenannt,
  Chief Human Resources Officer
• David P King,
  Director
• M. Huff Gary,
  CEO, LabCorp Diagnostics
• John D Ratliff,
  CEO, Covance Drug Development
• F Samuel Iii Eberts,
  Chief Legal Officer, Secretary
• Robert E Jr Mittelstaedt,
  Director
• Kathryn E Wengel,
  Director
• Thomas Pike,
  Pres & CEO Clinical Business
• Arthur H Rubenstein,
  Director
• M Keith Weikel,
  Director
• William B Hayes,
  Sr. Vice President
• Wendy E Lane,
  Director
• Lidia Fonseca,
  Chief Information Officer
• Bradford T Smith,
  EVP, Chf Legal Offcr,Secretary
• Don M Hardison,
  EVP, COO
• Mahon Thomas P Mac,
  CEO and Chairman of the Board
• N Anthony Coles,
  Director
• William Haas,
  EVP, Sales & Marketing
• Andrew J Conrad,
  EVP, Chief Scientific Officer
• Goldman Myla Lai,
  EVP & Chief Medical Officer
• Benjamin R Miller,
  EVP, Oncology Products & Serv
• Andrew G Wallace,
  Director
• Allen W Troub,
  EVP, Western Operations
• Woodrow L Cook,
  EVP, Eastern Operations
• Richard L Novak,
  EVP & Strategic Planning
• Deborah L Keller,
  CEO, Covance Drug Development
• James T. Jr. Boyle,
  Senior Vice President
• Joseph L Herring,
  CEO of Covance Drug Division
• Mark E Brecher,
  Chief Medical Officer
• Kirsten Marie Kliphouse,
  Director
• Paul Rothman,
  Director
• Jonathan P. Di Vincenzo,
  EVP, Pres, Central Labs & Intl
• Megan D. Bailey,
  EVP, Chief Strategy Officer